In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.
In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.
Novopharm was fined for failure to comply with a court order to disclose documents pertaining to the drug Lovastatin, for secretly resuming research on the product and for making submissions to the government using illegally retained documents.
According to a statement issued by Associate Chief Justice Oliphant, Novopharm's actions were motivated by a desire to bring Lovastatin to market before rival products, such as those produced by pharmaceutical company Apotex Inc. "The contemptuous conduct here was, I believeâ¦fueled by what must be one of the most bitter business rivalries I have ever witnessed," Oliphant said.
In the past, Novopharm was held liable for misappropriation of technology from a fermentation facility in Winnipeg owned by Apotex.
As a result, Novopharm cannot use the technology and was ordered to pay damages to Apotex in the amount of $6.5 million.
In addition to the most recent fine of $1.25 million, the court also ordered Novopharm to pay all of the legal costs that Apotex incurred as a result of the contempt proceedings. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.